|
|
|
|
| LEADER |
04758nam a2200529 4500 |
| 001 |
on1007309836 |
| 003 |
OCoLC |
| 005 |
20180501122038.0 |
| 006 |
m o d |
| 007 |
cr |n||||||||| |
| 008 |
171025s2017 maua ob 000 0 eng d |
| 040 |
|
|
|a YDX
|b eng
|c YDX
|d N$T
|d IDEBK
|d N$T
|d EBLCP
|d OPELS
|d UPM
|d OCLCF
|d OHS
|d OCLCO
|e rda
|d MEU
|d D6H
|d GrThAP
|
| 019 |
|
|
|a 1007130083
|a 1028923634
|a 1029499755
|a 1030777752
|
| 020 |
|
|
|a 9780128126394
|q (electronic bk.)
|
| 020 |
|
|
|a 0128126396
|q (electronic bk.)
|
| 020 |
|
|
|a 9780128126387
|
| 020 |
|
|
|a 0128126388
|
| 035 |
|
|
|a (OCoLC)1007309836
|z (OCoLC)1007130083
|z (OCoLC)1028923634
|z (OCoLC)1029499755
|z (OCoLC)1030777752
|
| 050 |
|
4 |
|a QP552.P4
|b .P478 2018eb
|
| 072 |
|
7 |
|a SCI
|x 008000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 572/.65
|2 23
|
| 082 |
0 |
4 |
|a 574.19/2456
|2 23
|
| 049 |
|
|
|a TEFA
|
| 245 |
0 |
0 |
|a Peptidomics of Cancer-Derived Enzyme Products /
|c edited by Tony Y. Hu, Fuyuhiko Tamanoi.
|
| 250 |
|
|
|a First edition.
|
| 264 |
|
1 |
|a Cambridge, MA :
|b Academic Press,
|c [2017].
|
| 300 |
|
|
|a 1 online resource (xvi, 172 pages :
|b illustrations).
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 546 |
|
|
|a Text in English.
|
| 504 |
|
|
|a Includes bibliographical references.
|
| 505 |
0 |
|
|a ""Front Cover""; ""Peptidomics of Cancer-Derived Enzyme Products""; ""Copyright""; ""Contents""; ""Contributors""; ""Preface""; ""Overview""; ""1. Molecular Changes in Cancer""; ""2. Peptidomes and Advance in Mass Spectrometry""; ""3. Nanotechnology and Nanodevices""; ""4. Future Perspective""; ""Chapter One: Circulating Peptidome and Tumor-Resident Proteolysis""; ""1. Introduction""; ""1.1. Intracellular Proteases""; ""1.1.1. Caspases (Cysteine Protease)""; ""1.1.2. Deubiquitinases (Cysteine and Zinc Proteases)""; ""1.1.3. Autophagins (Cysteine Proteases)""; ""1.2. Extracellular Proteases""
|
| 505 |
8 |
|
|a ""1.2.1. Matrix Metalloproteinases""""1.2.2. Cysteine Cathepsins""; ""1.2.3. Kallikreins""; ""2. Organism and Cancer Degradomes""; ""3. Tumor-Associated Peptidomics""; ""4. Tumor Proteases Relative Peptide in Cancer Detection""; ""5. Conclusion""; ""References""; ""Chapter Two: The Peptidome Comes of Age: Mass Spectrometry-Based Characterization of the Circulating Cancer Peptidome""; ""1. Introduction""; ""2. Biological Role of Peptides""; ""3. Peptidomics: The Study of Physiological Peptides""; ""4. Mass Spectrometry and Top/Middle-Down Proteomics""
|
| 505 |
8 |
|
|a ""4.1. Mass Spectrometry Technology Developments for Peptidomics""""4.2. Top-Top-Down or Native Mass Spectrometry""; ""4.3. Top-Down-Based Mass Spectrometric Imaging""; ""5. Strategies to Enrich the Peptidome""; ""5.1. Selective Precipitation""; ""5.2. Centrifugal Ultrafiltration""; ""5.3. Capillary Ultrafiltration""; ""5.4. Surface-Derivatised Magnetic Beads""; ""5.5. Nanoporous Substrates""; ""6. Application of Peptidomics in Cancer Biomarker Discovery""; ""6.1. Role of Peptidomics as in Cancer Biomarker Discovery""; ""6.2. Peptidomics and Cancer Diagnosis""
|
| 505 |
8 |
|
|a ""6.3. Plasma Protein/Peptide Profiling""""6.4. The Plasma Interactome""; ""6.5. Endoproteolytic Cleavage""; ""6.6. Exoproteolytic Cleavage""; ""7. Data Processing and Informatics for Peptidome Analyses""; ""7.1. Sequence Databases""; ""7.2. Data Analyses""; ""7.3. Data Repository""; ""8. Emerging Technologies""; ""9. Future Perspectives""; ""Acknowledgments""; ""References""; ""Chapter Three: Peptide Hormones as Tumor Markers in Clinical Practice""; ""1. Introduction""; ""2. Selected Peptide Hormones as Tumor Markers""; ""2.1. Calcitonin""; ""2.1.1. Biosynthesis From Prohormone""
|
| 505 |
8 |
|
|a ""2.1.2. Clinical Significance as Tumor Marker""""2.2. Alpha- and Beta-hCG""; ""2.2.1. Processing of hCG""; ""2.2.2. Clinical Applications as Tumor Markers""; ""2.3. Insulin and C-Peptide""; ""2.3.1. Biosynthesis From Prohormone""; ""2.3.2. Clinical Significance as Tumor Marker""; ""2.4. PTHrp""; ""2.4.1. Biosynthesis From Prohormone""; ""2.4.2. Clinical Significance as Tumor Marker""; ""2.5. Gastrin""; ""2.5.1. Biosynthesis From Prohormone""; ""2.5.2. Clinical Significance as Tumor Marker""; ""2.6. VIP""; ""2.6.1. Biosynthesis From Prohormone""
|
| 650 |
|
0 |
|a Peptides
|x Analysis.
|
| 650 |
|
2 |
|a Peptides
|x analysis.
|0 (DNLM)D010455Q000032
|
| 650 |
|
7 |
|a SCIENCE / Life Sciences / Biology.
|2 bisacsh
|
| 650 |
|
7 |
|a Peptides
|x Analysis.
|2 fast
|0 (OCoLC)fst01057565
|
| 655 |
|
4 |
|a Electronic books.
|
| 700 |
1 |
|
|a Hu, Xiaohua,
|d 1960-
|e editor.
|
| 700 |
1 |
|
|a Tamanoi, Fuyuhiko,
|e editor.
|
| 776 |
0 |
8 |
|c Original
|z 9780128126387
|z 0128126388
|w (OCoLC)985078856
|
| 830 |
|
0 |
|a Enzymes ;
|v v. 42.
|
| 856 |
4 |
0 |
|u https://www.sciencedirect.com/science/bookseries/18746047/42
|z Full Text via HEAL-Link
|
